BlossomHill Therapeutics Inc, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71 million in Series A financing. The investors included Cormorant Asset Management, Hercules BioVentures Partners LLC, OrbiMed Advisors and Vivo Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: